PDCD1 and cancer: The development of immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1), or its ligand (PD-L1) is a milestone in cancer therapy.